Scott Bizily - Jun 8, 2023 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Role: Chief Legal and HR Officer
Signature: /s/ August Moretti as Attorney-in-fact for Scott Bizily
Stock symbol: FDMT
Transactions as of: Jun 8, 2023
Transactions value $: -$48,038
Form type: 4
Date filed: 6/12/2023, 06:23 PM
Previous filing: Jun 6, 2023
Next filing: Dec 13, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FDMT	Common Stock	Options Exercise	$30.2K	+3.75K	+215.89%	$8.04	5.49K	Jun 8, 2023	Direct	F1
transaction	FDMT	Common Stock	Sale	-$78.2K	-3.75K	-68.34%	$20.85	1.74K	Jun 8, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FDMT	Stock Option (Right to Buy)	Options Exercise	$0	-3.75K	-7.14%	$0.00	48.8K	Jun 8, 2023	Common Stock	3.75K	$8.04	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person intended to comply with the prior version of rule 10b5-1.
F2	The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Content

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person intended to comply with the prior version of rule 10b5-1.

The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.